高血圧に対するバクスドロスタットの有効性と安全性：3つの第2/3相ランダム化比較試験の系統的レビューとメタアナリシス
Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2/3 Randomized Controlled Trials.
Falodia Rahul, Alokozay Ehsanullah, Idrees Mohammad, Paghdar Darsh ほか — Clinical cardiology
AI要約
治療抵抗性高血圧の新薬バクスドロスタットは、臨床試験で血圧を効果的に下げ（収縮期血圧9～14mmHg減）、選択性も高いです。高カリウム血症はモニタリングで管理可能ですが、長期的な効果と安全性の確認にはさらなる研究が必要です。
AI生成の要約です — 原文を読む
Abstract（原文）
BACKGROUND: Baxdrostat is a selective aldosterone synthase (CYP11B2) inhibitor for treatment-resistant and uncontrolled hypertension, evaluated in phase 2/3 RCTs. OBJECTIVES: To estimate pooled placebo-corrected reductions in seated office and ambulatory SBP, characterize the dose-response relationship, assess cortisol selectivity, and quantify hyperkalemia risk. METHODS: We conducted a systematic review and meta-analysis of phase 2/3 randomized, double-blind, placebo-controlled trials of baxdrostat in hypertension, searching MEDLINE/PubMed, EMBASE, ClinicalTrials.gov, and NEJM.org to March 2026. The primary outcome was placebo-corrected change in seated office SBP, analyzed using random-effects meta-analysis (REML) with metafor in R. Risk of bias and certainty were evaluated using Cochrane RoB 2.0 and GRADE, respectively. RESULTS: Three RCTs (BrigHTN, BaxHTN, Bax24; N = 1285) were included. The pooled seated SBP reduction was -9.44 mmHg (95% CI: -11.09 to -7.79; I = 0.0%), with dose subgroup estimates of -8.57 mmHg (1 mg) and -10.11 mmHg (2 mg) and a clear dose-response in BrigHTN (slope -4.2 mmHg/mg; R = 0.96). Bax24 demonstrated a 24 h ambulatory SBP reduction of -14.0 mmHg (95% CI: -17.2 to -10.8). Serum cortisol was unsuppressed at all doses, while the pooled OR for potassium ≥ 6.0 mmol/L was 5.14 (95% CI: 1.76 to 14.97). GRADE certainty was moderate for seated SBP, low to moderate for ambulatory outcomes, and low for hyperkalemia. CONCLUSIONS: Baxdrostat produces meaningful, selective BP reductions across hypertensive populations. Hyperkalemia is manageable with structured monitoring. Certainty is limited by a few trials, a short follow-up, and safety imprecision. Long-term cardiovascular outcome data are needed before guideline incorporation.
このコラムに関連する書籍
高血圧を食事で改善する――DASH食と減塩の実践ガイド
循環器・栄養学関連書籍
カリウムを増やしナトリウムを減らすDASH食の実践法を、日本の食材・料理に合わせて解説。
Amazonで本を見るおいしい減塩レシピ――1日6g以下を無理なく続ける
管理栄養士監修
塩分を抑えながら満足度の高い食事を実現するコツとレシピを紹介。カリウム食材の活用法も掲載。
Amazonで本を見るAmazonのアソシエイトとして、栄養DBは適格販売により収入を得ています。
出典: PubMed (PMID: 42334050)。AI要約は情報提供のみを目的とし、医療的アドバイスを構成するものではありません。